New diabetes drug imeglimin takes on metformin in mitochondrial showdown

NCT ID NCT07436182

Not yet recruiting Disease control Sponsor: Mansoura University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compares two diabetes medications—imeglimin and metformin—in 176 adults newly diagnosed with type 2 diabetes. Participants will take one of the two drugs for 12 weeks. The main goal is to see which drug better improves mitochondrial function, measured by a blood test called the pyruvate/lactate ratio. Researchers will also check blood sugar control and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imeglimin and metformin
What this could lead to: If imeglimin works better than metformin at improving mitochondrial function, it could offer a new first-line treatment option for type 2 diabetes.
What could go wrong: This is a small, early-phase trial (176 people) that hasn't started yet. It measures a biomarker (pyruvate/lactate ratio) rather than long-term outcomes, so success here may not translate to better diabetes control or fewer complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METFORMIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METFORMIN MITOCHONDRIA

Contacts and locations

Locations

Mansoura university hospitals

Al Mansurah, Province, 31951, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.